C2 CryoBalloon™ Ablation




A vital part of your comprehensive offering for patients with Barrett's esophagus with dysplasia [1,2].

Patients experienced less post-procedure pain and need for narcotic medication [4].


Highly effective and durable response through 2 years:

1-year results:

95% CED

88% CEIM


2-year results:

95% CED




Ready to ablate a wide range of patients

  • Highly effective in both naive and refractory patients with Barrett's esophagus
  • New catheter designs reach tubular structures, gastroesophageal junction (GEJ), and lesions big and small


C2 CryoBalloon™ 90° Standard Catheter ablating treatment naive tissue

C2 CryoBalloon™ Focal Pear Catheter at GEJ






To discover the full C2 CryoBalloon™ experience click here.



 1. Wani S, Muthusamy VR, Shaheen NJ, Yadlapati R, Wilson R, Abrams JA, et al. Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium. Am J Gastroenterol. 2017;112(7):1032-1048.

2. Canto MI, Shaheen NJ, Almario JA, Voltaggio L, Montgomery E, Lightdale CJ. Multifocal nitrous oxide cryoballoon ablation with or without EMR for treatment of neoplastic Barrett’s esophagus (with video). Gastrointest Endosc. 2018. [Epub ahead of print]

3. Canto MI. Safety, efficacy, and durability of endoscopic nitrous oxide cryoballoon ablation for eradication of Barrett’s neoplasia. Poster to be presented at: Digestive Disease Week; June 2-5, 2018. Washington, DC.

4. Van Munster SN, Overwater A, Haidry R, Bisschops R, Bergman J, Weusten BL. CryoBalloon ablation of dysplastic Barrett’s esophagus causes shorter duration and less severe post-procedural pain as compared to radiofrequency ablation. Oral presentation to be presented at: Digestive Disease Week; June 2-5, 2018. Washington, DC.